Exchange Surveillance
No active ASM or GSM measures on this stock.
Price band — none
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Cipla Ltd focuses on the development of new formulations and has a wide range of pharmaceutical products. They offer prescription drugs, bulk drugs, animal products , pesticides, a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.The company offers drugs used for the treatment of cancer, Alzheimer`s, arthritis, Parkinsons, cardiovascular diesases,drugs that prevents transmission of AIDS from mother to child, provide consulting services on preparation of products and materials, conducts plant evaluation and supplies plant equipments. They have also recently launched a number of products like an oral emergency contraceptive pill under the brand name I-Pill, a breakthrough screening technology in India called the No Touch Breast Scan (NTBS); ` the first-ever painless, non-invasive and radiation-free breast scanning technique for detecting breast cancer at an early stage and a generic versions of anti-flu drugs oseltamivir and zanamivir in the local market to treat the H1N1 influenza.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Mumbai, Maharashtra
- Chairman
- Y K Hamied
- CEO & MD
- Umang Vohra
- Registrar
- KFIN Technologies Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE059A01026
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Cipla Ltd today?
Cipla Ltd (CIPLA) is trading at ₹1,330.9. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is CIPLA’s P/E ratio versus the sector?
CIPLA trades at a P/E of 32.3. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is CIPLA’s dividend yield?
CIPLA has a dividend yield of 0.99%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is CIPLA’s 52-week high and low?
CIPLA has traded between ₹1,165.7 and ₹1,673 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Cipla Ltd?
Cipla Ltd has a market capitalisation of ₹1.06 lakh crore.
▶What is CIPLA’s return on equity?
CIPLA reports a return on equity of 10.4%. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are CIPLA’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is CIPLA’s promoter holding?
Promoters hold 29.22% of CIPLA. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include CIPLA?
Index membership is listed in the Context block on this page, along with the weight CIPLA carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Cipla Ltd a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from CIPLA’s own numbers. The judgement is yours.
CIPLA at a glance
Cipla Ltd operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Cipla Ltd (CIPLA) last traded at ₹1,330.9, giving it a market capitalisation of ₹1.06 lakh crore. The 52-week range is ₹1,165.7 to ₹1,673, and the price is 33% of the way up that range. It trades at a price-to-earnings ratio of 32.3. Promoters hold 29.22% of the company in the latest shareholding filing.
| Market cap | ₹1.06 lakh crore |
|---|---|
| P/E | 32.3 |
| ROE | 10.4% |
| ROCE | 13.7% |